CABA Cabaletta Bio

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:

  • Morgan Stanley 20th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, September 12, 2022 at 1:05 p.m. ET in New York, NY.
  • H.C. Wainwright 24th Annual Global Investment Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, September 14, 2022 at 9:30 a.m. ET in New York, NY.

A live webcast of these presentations will be available on the News and Events section of the Company’s website at . Replays will be available on the website for 30 days.

About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit and follow us on LinkedIn.

Contacts:

Anup Marda

Chief Financial Officer

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200



EN
06/09/2022

Underlying

CABACabaletta Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cabaletta Bio

 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in My...

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts        – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of...

May 15, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Resu...

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operat...

March 31, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care C...

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News and Even...

February 26, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating D...

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off or tapering steroids as of the latest follow-up – – Safety profile continues to suggest favorable risk-benefit in the first 10 p...

February 18, 2025 1 EN
 PRESS RELEASE
Free
CABA CABALETTA BIO

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening ...

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings – Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosuppressants and are off steroids as of the latest follow-up – – Safety profile continues to suggest favorable risk-benefit in the first 10 patients dosed; 90% of...

February 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch